Scholarlink

Abstract <p>To explore the clinical efficacy of manual reduction combined with betahistine hydrochloride tablets in treating benign paroxysmal positional vertigo (BPPV). A retrospective analysis of 80 BPPV cases (from September 2020 to October 2022) was randomly assigned to a study group (treated with manual reduction and betahistine hydrochloride tablets) or a control group (treated with manual reduction alone). Parameters including blood flow velocity in the vertebral and basilar arteries, balance scores, vestibular symptom index, dizziness scale scores, clinical efficacy, and recurrence rates were observed and compared. Before treatment, no significant differences existed between the groups. After treatment, the study group showed significantly higher blood flow velocity in the left vertebral artery (LVA), right vertebral artery (RVA), and basilar artery (BA) compared to the control group (<i>p</i> &lt; 0.05). Balance scores increased, and vestibular symptom index and dizziness scale scores decreased in both groups, with the study group exhibiting superior outcomes (<i>p</i> &lt; 0.05). The total effective rate in the study group (95.00%) surpassed that in the control group (77.50%) (<i>p</i> &lt; 0.05). During follow-up, the recurrence rate was lower in the study group (5.00%) compared to the control group (22.50%) (<i>p</i> &lt; 0.05).Combining manual reduction with betahistine hydrochloride tablets for BPPV treatment enhances blood flow, corrects symptoms, improves clinical efficacy, and reduces recurrence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Efficacy of Manual Reduction Combined with Betahistine Hydrochloride Tablets in the Treatment of Benign Paroxysmal Positional Vertigo

  • 期刊论文

  • 发表日期：

    2025年3月1日

查看全文
  • Linyan Zhang,
  • Wenlong Luo,
  • Chaoyong Wang

摘要

Abstract

To explore the clinical efficacy of manual reduction combined with betahistine hydrochloride tablets in treating benign paroxysmal positional vertigo (BPPV). A retrospective analysis of 80 BPPV cases (from September 2020 to October 2022) was randomly assigned to a study group (treated with manual reduction and betahistine hydrochloride tablets) or a control group (treated with manual reduction alone). Parameters including blood flow velocity in the vertebral and basilar arteries, balance scores, vestibular symptom index, dizziness scale scores, clinical efficacy, and recurrence rates were observed and compared. Before treatment, no significant differences existed between the groups. After treatment, the study group showed significantly higher blood flow velocity in the left vertebral artery (LVA), right vertebral artery (RVA), and basilar artery (BA) compared to the control group (p < 0.05). Balance scores increased, and vestibular symptom index and dizziness scale scores decreased in both groups, with the study group exhibiting superior outcomes (p < 0.05). The total effective rate in the study group (95.00%) surpassed that in the control group (77.50%) (p < 0.05). During follow-up, the recurrence rate was lower in the study group (5.00%) compared to the control group (22.50%) (p < 0.05).Combining manual reduction with betahistine hydrochloride tablets for BPPV treatment enhances blood flow, corrects symptoms, improves clinical efficacy, and reduces recurrence.